Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet's disease.
OBJECTIVE
To report our experience with intravitreal triamcinolone acetonide (IVTA) injections for the treatment of sight-threatening vitritis.


METHODS
Interventional case series.


METHODS
Three patients with acute severe exacerbations of noninfectious panuveitis and vitritis were treated with IVTA injections alone or as an adjunct to systemic immunosuppressive agents.


RESULTS
Rapid clearance of the vitreous inflammation with improvement in visual acuity was observed 1 to 2 weeks after injection. The effect lasted 2 to 6 months, with the shortest duration in the vitrectomized eye of Patient 1. Repeated injections were required in all patients.


CONCLUSIONS
Intravitreal triamcinolone acetonide may be beneficial in selected cases of vitritis. This treatment modality has a rapid effect and may lower the use of systemic agents.
Department of Ophthalmology, Rabin Medical Center, Petah Tiqva, Israel. umkramer@netvision.net.il
Michal
M
Kramer
Rita
R
Ehrlich
Moshe
M
Snir
Ronit
R
Friling
Masha
M
Mukamel
Dov
D
Weinberger
Ruth
R
Axer-Siegel
D000208:Acute Disease; D000293:Adolescent; D001528:Behcet Syndrome / Q000150:complications / Q000188:drug therapy*; D005128:Eye Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide